Despite the growth potential in Galenika's home country of Serbia, Valeant was the only suitor so far willing to enter a market rife with corruption. Now, it has backed out of its offer to buy the ailing state-run drugmaker amid agitation in Belgrade over privatization.
Malaysia's local device manufacturers and distributors expect major growth in original equipment manufacturing (OEM) demand from U.S. device clients, driven by double-digit growths in domestic device consumption and also surging business overseas.
Boehringer Ingelheim sees a wealth of opportunity in China's burgeoning pharma scene, and the German drug giant is plotting to open a contract manufacturing facility in Shanghai to cash in on biologics demand.
Indian drugmakers have faced compulsory licenses, parochial attitudes about patents and expanded price controls, and government actions. But when citizens in India are unhappy about how drugmakers are acting, they have tools to wield as well, and India's generic giant Ranbaxy Laboratories has just become a target.
Lots of international drugmakers are opening plants in China to manufacture their products for a growing middle class looking for Western medicines. But Germany's Boehringer Ingelheim is taking a different tact. It will build a biologics plant there and offer contract manufacturing to the growing number of Chinese companies developing their own drugs.
Sanofi is gearing up for commercial production at an insulin plant in Russia which it bought in 2010 from a Polish company.
Biocon's Kiran Mazumdar-Shaw has been one of the leaders in India attempting to build a biotech community capable of developing drugs for worldwide markets. Now the company has a test case on its hands.
India's Central Glass and Ceramic Research Institute is on track to becoming either hip replacement manufacturers' worst enemy, or a vital source of new technology. It has developed a ceramic-coated hip prototype that would cost a fraction of the cost of competing products currently in the marketplace.
DKSH, the Asia-focused drug marketer, has expanded its heft in South Korea, opening a new distribution in Seoul aimed to help its medical device clients place products around the country.
There's no shame in a company extending a bidding deadline in hopes of attaining a better offer. But after extending its deadline for the fourth time Thursday to June 14, Serbia's state-run drugmaker Galenika Pharmaceuticals may be starting to feel a bit unwanted.